John Panter, PA
Physician Assistant · Albuquerque, NMNPI 1407294655
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 231 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 26.4% of the total. Among physician assistant clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 231 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$936
- Pfizer$420
- AstraZeneca$227
- Novo Nordisk$219
- Boehringer Ingelheim$187
- Lilly USA, LLC$164
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,542100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 82 | $936 |
| Pfizer | 31 | $420 |
| AstraZeneca | 14 | $227 |
| Novo Nordisk | 13 | $219 |
| Boehringer Ingelheim | 9 | $187 |
| Lilly USA, LLC | 10 | $164 |
| GSK | 7 | $124 |
| Otsuka America Pharmaceutical, Inc. | 6 | $113 |
| Astellas Pharma US Inc | 5 | $112 |
| Novartis | 5 | $89 |
| Merck | 5 | $77 |
| Exact Sciences | 4 | $69 |
| Phathom Pharmaceuticals, Inc. | 4 | $67 |
| Abbott | 3 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $61 |
| Vertex | 2 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Lundbeck LLC | 2 | $46 |
| Inspire Medical Systems, Inc. | 1 | $42 |
| Seqirus USA Inc | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Sanofi Pasteur Inc. | 1 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Amgen | 2 | $31 |
| Mylan Specialty L.p. | 2 | $30 |
| Baxter Healthcare | 1 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Nevro Corp. | 1 | $29 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $25 |
| Viatris Specialty LLC | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Bioventus LLC | 1 | $16 |
| Axonics, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Angiodynamics, Inc. | 1 | $14 |
How this compares
$3,542 in reported general payments places this provider in the 95th percentile of 635 physician assistant providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 40 | $41,795 |
| Spiriva RespimatTiotropium Bromide | 39 | $32,251 |
| XareltoRivaroxaban | 21 | $26,851 |
| TrulicityDulaglutide | 17 | $24,621 |
| EliquisApixaban | 22 | $22,120 |
| JardianceEmpagliflozin | 14 | $20,181 |
| MyrbetriqMirabegron | 15 | $8,684 |
| Emgality PenGalcanezumab-Gnlm | 11 | $7,479 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,590 |
| Liothyronine Sodium | 115 | $6,547 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 146 | $3,935 |
| Epinephrine | 13 | $3,091 |
| Duloxetine Hcl | 74 | $2,935 |
| Pregabalin | 24 | $2,796 |
| Levothyroxine Sodium | 198 | $2,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat, Jardiance, Stiolto Respimat | $187 | $59,02266 claims |
| Novo NordiskOzempic | $219 | $41,79540 claims |
| Lilly USA, LLCTrulicity | $164 | $24,62117 claims |
| PfizerEliquis | $420 | $22,12022 claims |
| Astellas Pharma US IncMyrbetriq | $112 | $8,68415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 635 physician assistant providers in New Mexico.
Other physician assistant in Albuquerque
- Leigh HigginsAlbuquerque$10K
- Maria AbeytaAlbuquerque$8K
- Kari LavigneAlbuquerque$8K
- Elizabeth BelitzAlbuquerque$8K
- Desiree BarelaAlbuquerque$6K
- Stephanie BeyesAlbuquerque$5K
- Stephanie GonzalesAlbuquerque$5K
- Miquela WiegelAlbuquerque$5K
- Gabriela PobarAlbuquerque$5K
- Jacklyn ChavezAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.